The prognostic impact of anti-cancer immune response: a novel classification of cancer patients.
about
Can we negotiate with a tumor?Copy number variation analysis of matched ovarian primary tumors and peritoneal metastasisTh inducing POZ-Kruppel Factor (ThPOK) is a key regulator of the immune response since the early steps of colorectal carcinogenesis.Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy.Immune response gene expression in colorectal cancer carries distinct prognostic implications according to tissue, stage and site: a prospective retrospective translational study in the context of a hellenic cooperative oncology group randomised triPrediction model for regional or distant recurrence in endometrial cancer based on classical pathological and immunological parametersTrial watch: Chemotherapy with immunogenic cell death inducersInflammation in uveal melanomaAdenosine as an endogenous immunoregulator in cancer pathogenesis: where to go?Phenotypic and functional characteristics of CD4+ CD39+ FOXP3+ and CD4+ CD39+ FOXP3neg T-cell subsets in cancer patients.The relationship between lymphocyte subsets and clinico-pathological determinants of survival in patients with primary operable invasive ductal breast cancer.Evaluation of the immune factors in the tumor environment before and after the treatment of cetuximab combined with chemotherapy.Prognostic impact of immune microenvironment in laryngeal and pharyngeal squamous cell carcinoma: Immune cell subtypes, immuno-suppressive pathways and clinicopathologic characteristics.What are regulatory T cells (Treg) regulating in cancer and why?Can immuno-oncology offer a truly pan-tumour approach to therapy?Targeting the MHC Class II antigen presentation pathway in cancer immunotherapy.Therapeutic cancer vaccines: a long and winding road to success.Dissection of immune gene networks in primary melanoma tumors critical for antitumor surveillance of patients with stage II-III resectable disease.Low intratumoral regulatory T cells and high peritumoral CD8(+) T cells relate to long-term survival in patients with pancreatic ductal adenocarcinoma after pancreatectomy.Pathologic and imunohistochemical characterization of tumoral inflammatory cell infiltrate in invasive penile squamous cell carcinomas: Fox-P3 expression is an independent predictor of recurrence.Regulatory T-cell infiltration in tongue squamous cell carcinoma.Prognosis according to histochemical analysis of liver metastases removed at liver resection.Modulation of peripheral immune responses by paclitaxel-ifosfamide-cisplatin chemotherapy in advanced non-small-cell lung cancer.Chemotherapy ± cetuximab modulates peripheral immune responses in metastatic colorectal cancer.Development of a reliable and accurate algorithm to quantify the tumor immune stroma (QTiS) across tumor types.Prognostic value of tumor infiltrating lymphocyte subsets in breast cancer depends on hormone receptor status.Evolving notions on immune response in colorectal cancer and their implications for biomarker development.A Novel Immune Marker Model Predicts Oncological Outcomes of Patients with Colorectal Cancer.The clinical significance of memory T cells and its subsets in gastric cancer.Immunotherapy for Breast Cancer: Current and Future Strategies.Soluble NKG2D ligands are biomarkers associated with the clinical outcome to immune checkpoint blockade therapy of metastatic melanoma patients.Prechemotherapy neutrophil : lymphocyte ratio is superior to the platelet : lymphocyte ratio as a prognostic indicator for locally advanced esophageal squamous cell cancer treated with neoadjuvant chemotherapy.Quantitative and Qualitative Analysis of Tumor-Associated CD4⁺ T Cells.Integrative analysis reveals distinct subtypes with therapeutic implications in KRAS-mutant lung adenocarcinoma
P2860
Q28541524-A4998D07-8804-4A6E-BE1C-EA6BE7AA7724Q34110125-CE5C6CF8-A26C-41AA-AFA8-A56E8DD64B87Q34563178-D9EFEA47-DBD5-487F-90AD-724801934B0AQ35227810-D5E9CB64-4727-4D78-8ECC-02E0286361B2Q35602966-DED4B5F4-889F-4D0C-8EA1-D98720B22CF9Q36027067-96CF92C9-A59E-4CDF-BB00-B7BD658132E2Q36038456-8B5BAA62-B638-4595-835D-1F5A198FAF31Q36615048-7F7D78C2-5CBA-484D-85C7-1C8185F5E76FQ36821572-7FDFF40F-4B1A-435E-9F9E-2C9F7235EB71Q36946028-647CEBAC-F844-475C-95E3-6DCAC952F43CQ37182278-0089BD42-4148-4E5B-9CC8-24D931DAE225Q37357855-954C2F0F-35BB-4A2E-955A-9A86CDD79E37Q37745995-0DF3F72B-7477-4F23-9628-611822106091Q37998754-D8676FB8-7BE3-46B9-97E4-3D450B63AA97Q38037493-9B344C1C-7DB5-4B4B-8901-75C23F292DC4Q38060734-26DCFE7C-AB72-4DEC-ACF7-F26C0ED0446EQ38162261-39F2EC06-F088-4C3E-832A-8B9D2864F06DQ38441450-B7A851DD-13A9-45C8-9554-4C540010CD05Q41066538-AC238B62-881C-4777-AE18-EECB2FED4475Q41626811-7ECCCC14-08E9-4677-944B-17352F31FFDBQ43778066-6C0079D0-9646-4447-A418-C5B684E7CD08Q45834310-8150ED4D-56D6-4DF2-83CA-7F4165998C70Q45912169-7EF568D3-889B-4628-9513-D87F1CF01DE3Q46009100-6C49FA73-636F-4AD5-A007-E50D90A34CCBQ47554538-D7953EBB-C56F-4562-9672-A9719928A44FQ48182026-95793249-62FD-4A0E-BC28-17F1BB276DEFQ50098505-B0547681-6930-41AB-9F7C-E76995D9B29AQ50770591-BBD37EAF-1264-4748-A3E4-449D50AC0391Q50894985-99832A33-FC42-40DA-94F9-338DA4EB72C1Q52587066-9A6E2F8D-DCAF-40FA-9C01-2D7A840DC9CDQ52758918-7DE64DFF-CAA0-4E4B-B5B3-932F8378295AQ53634507-6FF0BD3B-E517-482B-9015-4C06DB3BBD9EQ54518729-735611B1-830A-462B-9388-722A40CD6FADQ59127131-B549B8FF-6DF8-48A5-99EE-22A3E2AD2C3D
P2860
The prognostic impact of anti-cancer immune response: a novel classification of cancer patients.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 05 April 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The prognostic impact of anti- ...... sification of cancer patients.
@en
The prognostic impact of anti- ...... sification of cancer patients.
@nl
type
label
The prognostic impact of anti- ...... sification of cancer patients.
@en
The prognostic impact of anti- ...... sification of cancer patients.
@nl
prefLabel
The prognostic impact of anti- ...... sification of cancer patients.
@en
The prognostic impact of anti- ...... sification of cancer patients.
@nl
P2093
P2860
P1476
The prognostic impact of anti- ...... sification of cancer patients.
@en
P2093
Bernhard Mlecnik
Gabriela Bindea
Wolf-Herman Fridman
P2860
P2888
P304
P356
10.1007/S00281-011-0264-X
P577
2011-04-05T00:00:00Z
2011-07-01T00:00:00Z